Health Informatics And Implementation Science
Biostatistics And Health Services Research
Cutler Chair in Vascular and Endovascular Surgery
Robert M. and Shirley S. Siff Chair in Autism
Melvin S. and Sandra L. Cutler Chair in Biomedical Research
Dr. Henninger is a vascular neurologist with research interest in the neurobiology of axonal injury associated with traumatic brain injury and its contribution to functional outcome.
Imoigele P. Aisiku, MD’97 Chair in Health Equity and Diversity
Postdoctoral Fellow Applications are being accepted for one position. A position is available to develop Cys2His2 zinc finger proteins (ZFPs) for the treatment of monogenic disorders. This project will focus on the creation of ZFPs with novel DNA-binding specificity to recognize sequence elements within genomic loci of therapeutic interest. In collaboration with other laboratories, we will evaluate the activity of these ZFP-based gene therapy reagents in vitro and in vivo in relevant disease models. Applicants will also have the opportunity to learn to apply Cas9 and Cas12a editing systems in vivo.
Potential Rotation Projects Improving the Precision of CRISPR/Cas9 nucleases for gene therapy applications: We are working to improve the precision of the CRISPR/Cas9 system to generate nucleases that will cleave at only a single site in the genome. These engineering efforts focus on increasing the DNA-editing precision of Cas9 and using protein engineering to introduce new properties into the nuclease. Much of this work is now transitioning to the use of Cas9 (and Cas12a) protein-RNA complexes. These modified nucleases will then be applied to patient derived cell-culture systems for the targeted repair or inactivation of disease-causing alleles. With the eventual goal of creating therapeutics for Sickle Cell Disease, beta-Thalassemia, HIV, Limb Girdle Muscular Dystrophy, Hermansky Pudlak Syndrome and other monogenic disorders. ex vivo genome editing in CD34+ HSPCs: We are developing improved Cas9 proteins for delivery ex vivo into CD34+ HSPCs for therapeutic application to sickle cell disease and beta-thalassemia. The goal is to modify the hematopoietic stem cells of a patient to complement the loss of function of the beta-globin gene and then return these cells to the patient through an autologous transplant. Development of Cys2His2 Zinc fingers proteins (ZFPs) as targeted therapeutics: We are developing artificial ZFPs for the regulation of target genes to change their gene expression profiles for therapeutic applications.
Barbara Helen Smith Chair in Preventive & Behavioral Medicine
Richard M. Haidack Professor in Medicine
Dr. John Meyers Professor in Primary Care Medicine
Population and Quantitative Health Sciences
UMass Worcester Prevention Research Center
Prevention Research Center at UMass Chan
Tweets by @DrSherryPagoto
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Preventing Osteoarthritis After an ACL Injury
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA Characteristics of Accelerated Hand Osteoarthritis
Joseph D. Early Chair in Biomedical Research
Dr. Wilcox trained in EM at the Harvard Affiliated EM Residency, then completed an Anesthesia Critical Care fellowship. In addition to the ED, she has attended in Surgical, Medical, and Cardiac ICUs. She joined Lahey Hospital in 2022 as the Medical Director of the 5C Medical ICU. She is Vice Chair for Academic Affairs and a Professor of Medicine. She is the Associate CMO for Boston MedFlight.
EMCrit 181 – Pulmonary Hypertension and Right Ventricular Failure with Susan Wilcox
HarvardX: Mechanical Ventilation for COVID-19
CritCases 7 Pulmonary Hypertension – A Fine Balance
Academic Life in Emergency Medicine: The Myth of Vasopressors and Ischemia
ACEP COVID-19 Field Guide: ICU Care in the Emergency Department
Podcast summary of articles from the June 2021 edition of the Journal of Emergency Medicine